HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

IKK NBD peptide

synthetic peptide

Networked: 5 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cell-Penetrating Peptides: 734
    - IKK NBD peptide: 5

Experts

1.	Krause, Martin F: 4 articles (06/2012 - 06/2005)
2.	Schütze, Stefan: 3 articles (06/2012 - 10/2007)
3.	Winoto-Morbach, Supandi: 3 articles (06/2012 - 10/2007)
4.	von Bismarck, Philipp: 3 articles (06/2012 - 10/2007)
5.	Uhlig, Ulrike: 2 articles (06/2012 - 10/2007)
6.	Klemm, Karsten: 2 articles (08/2009 - 10/2007)
7.	Herzberg, Mona: 1 article (06/2012)
8.	Lucius, Ralph: 1 article (06/2012)
9.	Desai, Abhishek: 1 article (12/2010)
10.	Raghubir, Ram: 1 article (12/2010)

Related Diseases

1.	Pneumonia (Pneumonitis) 06/01/2012 - "IKK NBD peptide inhibits LPS induced pulmonary inflammation and alters sphingolipid metabolism in a murine model." 08/01/2009 - "At 24h of mechanical ventilation, inhibition of NF-kappaB activity by IKK-NBD peptide admixed to surfactant as a carrier caused improved gas exchange, lung function and reduced pulmonary inflammation, as evidenced by reduction in PMNL migration into lung tissue due to reduced nuclear NF-kappaB activity. " 10/01/2007 - "In this study, we tested the hypothesis that the topical use of a NF-[kappa]B inhibitor (I[kappa]B kinase-NF-[kappa]B essential modulator binding domain [IKK-NBD] peptide), together with surfactant as a carrier substance, improves surfactant function by attenuation of pulmonary inflammation during 24 hrs of mechanical ventilation in a neonatal piglet model of acute respiratory distress syndrome by repeated airway lavage. "
2.	Inflammation (Inflammations) 12/01/2010 - "Thus, it may be inferred that IKK-NBD peptide reduces ischemic brain damage and this can, at least partly, be attributed to reduction in inflammation following ischemic injury." 10/01/2007 - "After 20 +/- 6 (mean +/- sd) lavages to induce lung failure and inflammation, a porcine surfactant (100 mg/kg) with (S+IKK) or without (S) 1.25 mg of IKK-NBD peptide, or an air bolus (control) was administered into the airways. " 06/01/2005 - "The aim of this study was to investigate the effect of a topically applied nuclear factor-kappaB inhibitor (IkappaB kinase-NF-kappaB essential modulator binding domain [IKK-NBD] peptide) on gas exchange, lung function, lung fluids, and inflammation in a piglet model of repeated airway lavage that is characterized by surfactant deficiency, lung edema, and an inflammatory response. "
3.	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 10/01/2007 - "In this study, we tested the hypothesis that the topical use of a NF-[kappa]B inhibitor (I[kappa]B kinase-NF-[kappa]B essential modulator binding domain [IKK-NBD] peptide), together with surfactant as a carrier substance, improves surfactant function by attenuation of pulmonary inflammation during 24 hrs of mechanical ventilation in a neonatal piglet model of acute respiratory distress syndrome by repeated airway lavage. "
4.	Edema (Dropsy) 06/01/2005 - "The aim of this study was to investigate the effect of a topically applied nuclear factor-kappaB inhibitor (IkappaB kinase-NF-kappaB essential modulator binding domain [IKK-NBD] peptide) on gas exchange, lung function, lung fluids, and inflammation in a piglet model of repeated airway lavage that is characterized by surfactant deficiency, lung edema, and an inflammatory response. "
5.	Ischemia 12/01/2010 - "The assessment of ischemia-induced neurological deficits, alterations in the proinflammatory cytokine IL-1β level, OX-42 immunoreactivity, changes in blood-brain barrier (BBB) permeability, reactive oxygen species (ROS) production and DNA fragmentation by terminal dUTP nick end labelling (TUNEL) were monitored at 24h post reperfusion following 1h of ischemia after pre-treatment with either 40μg of IKK-NBD or the inactive IKK-NBD peptide, which served as control. "

Related Drugs and Biologics

1.	NF-kappa B (NF-kB)
2.	Surface-Active Agents (Surfactants)
3.	I-kappa B Kinase
4.	Reactive Oxygen Species (Oxygen Radicals)
5.	Cytokines
6.	Sphingolipids

Related Therapies and Procedures

1.	Artificial Respiration (Mechanical Ventilation)